COR — Stock Film
STOCK FILMSCENE 1/11COR · $315
Stock Expert AI presents
COR
Cencora, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Cencora, Inc. A quick introduction.

On the stock market since 1995, it operates in the world of health and science. It has 49,000 employees. Now — the numbers.

on the stock market since 1995
49K employees
$61B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, less than $1 stays as net profit.

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
89%Pharmaceutical Distribution
Pharmaceutical Distribution 89%Animal Health 2%Other 9%
89% of all revenue comes from a single line: Pharmaceutical Distribution.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 11% a year over the last 4 years. Every year shown ended in profit.

$214B
2021
$239B
2022
$262B
2023
$294B
2024
$321B
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
78
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
50
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
85
very strong

The price looks reasonable next to what the company earns.

GROWTH
88
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
51
average

The price is looking for direction — no strong breakout, no collapse.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Few are betting against it10/10
WEAK SPOTS
Thin profit on each sale3/10
The stock has lost its spark3/10
Costs eat into the margin4/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 16% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 10% a year on average.

2
THE BRIGHT SIDE · 2/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

3
THE BRIGHT SIDE · 3/3
Pays a steady dividend

It pays out $2.35 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
A rich price tag

The company’s market value is 39 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/3
Thin profit on each sale

As the slice kept from each sale thins out, so does the profit. Council score: 3/10.

3
THE RISKS · 3/3
The stock has lost its spark

Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.

FINALE · THE GRADE
B
0 / 100 · MoonshotScore

On our five-subject report card, COR sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: COR is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film